Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2003
03/20/2003US20030055045 Novel compounds with analgesic effect
03/20/2003US20030055044 Administering pyrazole derivative for inhibiting GSK-3 or Aurora activity in a patient
03/20/2003US20030055043 Substituted azabicyclic moieties for the treatment of disease
03/20/2003US20030055042 Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
03/20/2003US20030055040 Cholinesterase inhibitors to treat disorders of attention
03/20/2003US20030055039 For prophylaxis and therapy of inflammatory disease
03/20/2003US20030055037 Benzimidazole and indole derivatives as CRF receptor modulators
03/20/2003US20030055036 Method for treating a demyelinating condition
03/20/2003US20030055035 Useful in hyperpolarizing cell membranes, opening potassium channels, relaxing smooth muscle cells, and inhibiting bladder contractions
03/20/2003US20030055034 Preparing a concentrated inhalable aztreonam formulation comprising aztreonam dissolved in an aerosolable solution; delivering aztreonam dry powder or the aerosolable solution to the lung endobronchial space of airways of a patient
03/20/2003US20030055032 For therapy or inhibiting the development of a pathology associated with peroxynitrite damage
03/20/2003US20030055030 Administering 2(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride for therapy of inflammatory disease or inflammation-associated disorder
03/20/2003US20030055029 Combbretastatin a-4 as an anti-angiogenic agent
03/20/2003US20030055028 Administering two separate dosage forms of a topically active corticosteroid or a pharmaceutically active salt thereof for therapy ofinflammatory bowel disease and sufficient to reduce or eliminate side effects
03/20/2003US20030055027 For therapy of circulatory disorders, including cardiovascular disorders such as hypertension, congestive heart failure, cirrhosis and ascites
03/20/2003US20030055026 Formoterol/steroid bronchodilating compositions and methods of use thereof
03/20/2003US20030055025 For therapy of bacterial infections and neoplasms,
03/20/2003US20030055024 Administering in divided doses an effective amount of a vascular damaging agent or a pharmaceutically acceptable salt thereof for production of a vascular damaging effect in a warm-blooded animal such as a human
03/20/2003US20030055023 Injectable formulation of a sedative hypnotic drug, such as the anesthetic drug etomidate, that is pharmaceutically stable, demonstrates a reduced incidence of pain upon injection
03/20/2003US20030055022 Treatment for reactive arthritis or bursitis
03/20/2003US20030055021 Compounds for the treatment of ischemia
03/20/2003US20030055019 Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
03/20/2003US20030055015 Therapy and prophylaxis of diseases
03/20/2003US20030055014 Administering at least one antiangiogenic nucleic acid molecule in an amount effective to inhibit angiogenesis
03/20/2003US20030055012 Prodrugs of COX-2 inhibitors
03/20/2003US20030055011 Feeding emamectin or a salt thereof to said fish population at a daily dose of 25 mu g to 400 mu g per kg of fish biomass per day for a period of 3-14 days for eliminating, reducing or preventing parasites in a fish population
03/20/2003US20030055009 Administering a drug for stimulating hair growth, preventing hair loss, or retarding hair loss in a mammal
03/20/2003US20030055008 Anticonvulsant derivatives useful in treating psychosis
03/20/2003US20030055007 Antimicrobial agents
03/20/2003US20030055006 Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/tie receptor function and their use
03/20/2003US20030054998 Prolactin induced increase in neural stem cell numbers
03/20/2003US20030054996 Contacting complex comprising a GRP94 protein with a binding agent that is immobilized to a solid phase support, to immobilize the complex to solid phase support; collecting the remaining sample; eluting the complex from solid phase support
03/20/2003US20030054993 For contraception in a mammal, for therapy of infertility
03/20/2003US20030054990 Methods of using neural thread proteins to treat tumors and other conditions requiring the removal or destruction of cells
03/20/2003US20030054986 Novel DNA and to the recombinant production of novel polypeptides encoded by that DNA
03/20/2003US20030054984 Treating obesity and non-insulin-dependent (type II) diabetes mellitus (NIDDM) by specifically targeting the genes and gene products of cathepsins
03/20/2003US20030054981 Parenteral formulation of an echinocandin compound, the micelle-forming surfactant, and a nontoxic, aqueous solvent, in given weight ratio of surfactant to echinocandin; treating fungal infections
03/20/2003US20030054978 Arginine compound or conjugate thereof and one or more of a high molecular weight aliphatic alcohol and methyl donor cofactor and conjugates thereof
03/20/2003US20030054974 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof
03/20/2003US20030054525 UDP-N-acetylglucosamine: galactose-beta1,3-N-acetylgalactosamine-alpha-R / (GlcNAc to GalNAc) beta1,6-N-acetylglucosaminyltransferase, C2GnT3
03/20/2003US20030054512 Autoinducer synthase modulating compounds and uses therefore
03/20/2003US20030054508 Substantially pure glycopeptide antibotics AC-98-1; AC-98-2; AC-98-3; AC-98-4 AND AC-98-5
03/20/2003US20030054452 Lysolipid for use in controlling apoptosis and treating inflammatory and innumological disorders
03/20/2003US20030054446 Novel retina-specific human proteins C7orf9, C12orf7, MPP4 and F379
03/20/2003US20030054445 Polynucleotide encoding a novel human serpin secreted from lymphoid cells, LSI-01
03/20/2003US20030054409 Novel complex-forming proteins
03/20/2003US20030054405 Secreted and transmembrane polypeptides and nucleic acids encoding the same
03/20/2003US20030054379 Nucleotide sequences coding polypeptide for use in the treatment, diagnosis and prevention of cancer, immunological, viral and autoimmune disease
03/20/2003US20030054365 MHC class II antigen presenting cells containing oligonucleotides which inhibit Ii protein expression
03/20/2003US20030054357 Monitoring the proliferation of cultured prostate cancer cells; obtain cells, incubate with quercetin, monitor adjustment in gene expression, decrease in androgen receptor gene expression indicate cell proliferation inhibitor
03/20/2003US20030054341 Viral nucleotide sequences for use in diagnosis, prevention and treatment of viral diseases
03/20/2003US20030054082 Oil or fat composition
03/20/2003US20030054058 Vitex agnus castus extract
03/20/2003US20030054053 Methods and compositions for inhibiting the proliferation of prostate cancer cells
03/20/2003US20030054052 Triterpene compositions and methods for use thereof
03/20/2003US20030054051 Using emetine
03/20/2003US20030054048 Method of increasing the presence of glutathione in cells
03/20/2003US20030054042 Stabilization of chemical compounds using nanoparticulate formulations
03/20/2003US20030054041 Modified release formulations containing a hypnotic agent
03/20/2003US20030054038 Mixture of drug and enteric acid polymer; neutralization
03/20/2003US20030054037 Pharmaceutical compositions of adsorbates of amorphous drug
03/20/2003US20030054034 Water soluble film forming polymer and microbiocide oil
03/20/2003US20030054033 Sustained release; therapy for attention deficit disorders
03/20/2003US20030054032 Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
03/20/2003US20030054031 Controlled release oral dosage form
03/20/2003US20030054030 Topical applying mixture of active material and lipid; side effect reduction
03/20/2003US20030054029 Iib/iiia antagonists co-administered with aspirin
03/20/2003US20030054028 Sustained releasing drug in situ
03/20/2003US20030054026 Athletic patch
03/20/2003US20030054020 Method and composition for reducing sebum secretion in mammals
03/20/2003US20030054017 Alcohol based topical anesthetic formulation and method
03/20/2003US20030054015 Mixture of vegetable oil, aromatic solvent and caffeine; nerve stimulant perfume
03/20/2003US20030054003 Antitumor agents, anticarcinogenic agents
03/20/2003US20030053991 Retinoic acid receptor beta-2, its agonists, and gene theraphy vectors for the treatment of neurological disorders
03/20/2003US20030053987 Synthetic hepatitis c genes
03/20/2003US20030053986 Method of treating hepatitis C infection
03/20/2003US20030053981 Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
03/20/2003US20030053973 Topical composition for follicular delivery of an ornithine decarboxylase inhibitor
03/20/2003US20030053968 Compositions for the treatment of pigmentation disorders and methods for their manufacture
03/20/2003US20030053967 Use of 3,4-dihydroxy-mandelic acid for protecting against oxidative damage caused by ultra-violet light
03/20/2003US20030053960 Powder formulation
03/20/2003US20030053958 For treating pulmonary hypertension; sustained release; has no effect on heart rate
03/20/2003US20030053957 Degradation-resistant glucocorticosteroid formulations
03/20/2003US20030053956 Alkylaryl polyether alcohol polymers for treatment and prophylaxis of snoring, sleep apnea, sudden infant death syndrome and for improvement of nasal breathing
03/20/2003US20030051728 Method and device for delivering a physiologically active compound
03/20/2003CA2806723A1 Synthetic heparin pentasaccharides
03/20/2003CA2806604A1 Synthetic heparin pentasaccharides
03/20/2003CA2806561A1 Synthetic heparin pentasaccharides
03/20/2003CA2461692A1 Use of a protein of the crmp family for treating diseases related to the immune system
03/20/2003CA2460348A1 Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
03/20/2003CA2460347A1 3-glyoxlylamideindoles for treating cancer
03/20/2003CA2460345A1 2-aroylimidazole compounds for treating cancer
03/20/2003CA2460330A1 Method for the preparation of crystalline tetrahydrobenzothiepines
03/20/2003CA2460190A1 Transdermal administration of an enalapril ester
03/20/2003CA2460117A1 Expression profiling in the intact human heart
03/20/2003CA2460075A1 Substituted 7-aza[2.2.1] bicycloheptanes for the treatment of diseases
03/20/2003CA2460023A1 Method for treating coumarin-induced hemorrhage
03/20/2003CA2460022A1 Aryloxypropylamines as chemosensitizing agent in the treatment of cancer
03/20/2003CA2459973A1 Carbazole derivatives and their use as npy5 receptor antagonists
03/20/2003CA2459886A1 1-glyoxlylamide indolizines for treating cancer
1 ... 5529 5530 5531 5532 5533 5534 5535 5536 5537 5538 5539 5540 5541 5542 5543 5544 5545 5546 5547 5548 5549 ... 7860